French MedTech Startup Annette Raises €2M To Provide Structured GLP-1 Obesity Care Across Europe

The funding round was led by Redstone, Ring Capital, AFI Ventures (Ventech), Clover VC, and Gfund.

“We use both clinical and subjective data (satiety, energy, symptoms…) to synchronise the care team around each patient, detect early signals, and adjust at the right moment. Technology acts as a safety net: it augments the human touch – it never replaces it,” says Gwen Le Calvez, co-founder and Chief Product and Technology Officer, Annette.

Annette’s €2 million raise comes amid steady 2025 European investment in digital chronic-care and obesity-focused HealthTech. In Poland Holi secured €3 million to expand its data-driven obesity clinic, while Doctor.One raised €4 million to scale its asynchronous chronic-care model. In France, RDS raised €14 million to industrialise its remote-monitoring patch, highlighting continued investor confidence in French HealthTech.

Read Also - London’s Yuv Raises €10M To Scale Salon Technology After Setting Dragons’ Den Record

Together, these rounds represent roughly €21 million in adjacent chronic-care and monitoring solutions, rising to ~€23 million when including Annette. Within this context Annette stands out as one of the few French companies specifically focused on GLP-1–supported obesity care, reflecting the 2025 trend toward integrated, multidisciplinary chronic-care platforms across Europe.

“These results are not driven by the treatment alone: they occur when medication is paired with structure, nutritional guidance, emotional support, and a gradual adaptation to the body’s rhythm. This is precisely what Annette delivers – turning a treatment into a true long-term care pathway,” adds François-Xavier Trancart, co-founder and CEO, Annette.

Founded in 2024 by serial entrepreneurs François-Xavier Trancart (Artsper) and Gwen Le Calvez (Birdie), Annette delivers long-term GLP-1 and chronic obesity care through a multidisciplinary team coordinated via a companion app ensuring treatment safety and supporting patients in achieving sustainable, lasting results.

“At AFI Ventures, we back entrepreneurs who use technology to tackle society’s most pressing challenges. Obesity is clearly one of them. What makes us particularly enthusiastic about Annette is the rare combination of an ambitious vision, scientific rigor, and a product capable of creating meaningful impact for millions of people. We are convinced that the Annette team is building a solution that can truly move the needle,” says Constantin de Chaudenay, Investor at AFI Ventures

The introduction of GLP-1 treatments like Wegovy and Mounjaro is a major milestone in obesity care. However, international experience shows risks when these medications are used without proper supervision isolated prescriptions, limited follow-up, and significant weight regain. Annette addresses this gap by providing structured nutrition, emotional support, personalized physical activity, and continuous medical oversight.

“The treatment can reduce appetite. But it does not rewrite eating habits or the relationship with one’s body. Medical and behavioral support makes it possible to transform how one eats, moves, and feels. It is the combination of both that truly shifts the weight trajectory – and makes it last,” explains Dr Lysiane Jubin, Chief Medical Officer, Annette.

About Annette

Annette is a clinical companion app for GLP-1 treatments, providing personalized obesity care with medical expertise, nutritional guidance, emotional support and tailored physical activity. By combining structured human follow-up and coordinated medical oversight, Annette helps patients achieve lasting results and regain confidence.